US Stock MarketDetailed Quotes
PTGX Protagonist Therapeutics
- 43.800
- -1.150-2.56%
Close Nov 29 13:00 ET
2.61BMarket Cap15.99P/E (TTM)
45.258High43.590Low320.21KVolume44.590Open44.950Pre Close14.06MTurnover0.67%Turnover RatioLossP/E (Static)59.60MShares48.89052wk High4.91P/B2.08BFloat Cap18.07052wk Low--Dividend TTM47.53MShs Float50.540Historical High--Div YieldTTM3.71%Amplitude4.470Historical Low43.921Avg Price1Lot Size
About Protagonist Therapeutics Company
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Company Profile
SymbolPTGX
Company NameProtagonist Therapeutics
Listing DateAug 11, 2016
Issue Price12.00
Founded2006
CEODr. Dinesh V. Patel, PhD
MarketNASDAQ
Employees112
Fiscal Year Ends12-31
Address7707 Gateway Boulevard,Suite 140
CityNewark
ProvinceCalifornia
CountryUnited States of America
Zip Code94560-1160
Phone1-510-474-0170
Company Executives
- Name
- Position
- Salary
- Dr. Dinesh V. Patel, PhD
- Director, President and Chief Executive Officer
- 7.07M
- Dr. Suneel Gupta, PhD
- Chief Development Officer
- 2.22M
- Asif Ali
- Executive Vice President, Principal Accounting Officer and Chief Financial Officer
- 1.40M
- Dr. Arturo Molina, M.D.
- Chief Medical Officer
- --
- Dr. Harold E. Selick, PhD
- Chairman of the Board
- 395.27K
- Dr. Lewis T. Willia M.D.,PhD
- Independent Director
- 351.52K
- Sarah A. O’Dowd
- Independent Director
- 341.52K
- William D. Waddill
- Independent Director
- 364.02K
- Bryan Giraudo
- Independent Director
- 356.52K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data